Wang Yuan, He Jing, Xu Manyu, Xue Qingfeng, Zhu Cindy, Liu Juan, Zhang Yaping, Shi Wenyu
Department of Oncology, Affiliated Hospital of Nantong University, Nantong, China.
Nantong University School of Medicine, Nantong, China.
Front Oncol. 2022 Feb 8;12:815654. doi: 10.3389/fonc.2022.815654. eCollection 2022.
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase expressed at early stages of normal development and in various cancers including ALK-positive anaplastic large cell lymphoma (ALK+ ALCL), in which it is the main therapeutic target. ALK tyrosine kinase inhibitors (ALK TKIs) have greatly improved the prognosis of ALK+ALCL patients, but the emergence of drug resistance is inevitable and limits the applicability of these drugs. Although various mechanisms of resistance have been elucidated, the problem persists and there have been relatively few relevant clinical studies. This review describes research progress on ALK+ ALCL including the application and development of new therapies, especially in relation to drug resistance. We also propose potential treatment strategies based on current knowledge to inform the design of future clinical trials.
间变性淋巴瘤激酶（ALK）是一种受体酪氨酸激酶，在正常发育的早期阶段以及包括ALK阳性间变性大细胞淋巴瘤（ALK+ ALCL）在内的各种癌症中表达，在ALK+ ALCL中它是主要的治疗靶点。ALK酪氨酸激酶抑制剂（ALK TKIs）极大地改善了ALK+ ALCL患者的预后，但耐药性的出现不可避免，限制了这些药物的适用性。尽管已经阐明了各种耐药机制，但问题仍然存在，相关的临床研究相对较少。本综述描述了ALK+ ALCL的研究进展，包括新疗法的应用和开发，特别是与耐药性相关的进展。我们还根据现有知识提出了潜在的治疗策略，为未来临床试验的设计提供参考。
